With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

Diagram demonstrating three level recursion in female orangutan vocalisations ...

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across ...

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal ...

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not ...

Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger Recursion is working on 10 potential drugs, and has enough cash to fuel itself through 2027 Adobe ...